Cite
HARVARD Citation
Xu, B. et al. (2022). Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert opinion on investigational drugs. pp. 337-346. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Xu, B. et al. (2022). Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert opinion on investigational drugs. pp. 337-346. [Online].